News and Media

2017/06/07 – Quantum Genomics to host two upcoming events

7 June 2017
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular, is excited to confirm that it is hosting two significant events in the month of June […]

2017/05/23 – Quantum Genomics to Host Key Opinion Leader Event Focused on Phase IIa Hypertension Data and the Upcoming Clinical Trial in the United States

23 May 2017
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular, announced today that it will host a Key Opinion Leader (KOL) event for institutional investors and research analysts on June 27, 2017 […]

2017/05/09 – Quantum Genomics will organize a teleconference on June 19, 2017, to comment on phase IIa data in high blood pressure

9 May 2017
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, confirms that the study’s Principal Investigator, Prof. Michel Azizi, will present phase 2a results for the drug-candidate QGC001 at […]

2017/04/25 – Quantum Genomics appoints Bruno Besse as Chief Medical Officer

25 April 2017
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces the appointment of Dr Bruno Besse as the Company’s Chief Medical Officer.

Dr Besse will be in charge of […]

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next page ›